GISSI trial

GISSI trial
Name	GISSI trial
Acronym	GISSI
Country	Italy
Years	1989–1999
Participants	>11,000
Interventions	Streptokinase, Ticlopidine, ACE inhibitors, Thrombolytic therapy
Primary outcome	Mortality after Myocardial infarction

GISSI trial

The GISSI trial was a series of large-scale randomized studies conducted in Italy that evaluated interventions for acute Myocardial infarction and related cardiovascular conditions. Led by investigators associated with the Istituto di Ricerche Farmacologiche Mario Negri and coordinated through Italian cardiology networks including the GISSI group, the trials influenced clinical approaches in the era of thrombolysis, antiplatelet therapy, and neurohormonal blockade. The program’s findings were widely discussed at venues such as the European Society of Cardiology and the American Heart Association annual meetings.

Background

The program originated in the context of late 20th-century shifts in cardiology marked by landmark trials like ISIS-2, GUSTO, and TIMI studies investigating reperfusion and antithrombotic strategies. Cardiologists from institutions such as Ospedale Maggiore Policlinico and academic centers across Milan, Rome, and Naples sought pragmatic randomized evidence applicable to routine practice in Italian hospitals. The trials responded to contemporaneous changes in pharmacotherapy exemplified by agents like Streptokinase and evolving secondary prevention concepts championed by investigators linked to the World Health Organization and the European Commission research programs.

Trial design and methods

GISSI encompassed multiple randomized controlled trials enrolling more than 11,000 patients with acute Myocardial infarction and related syndromes. The core protocol used open-label, randomized allocations with endpoints including all-cause mortality and reinfarction, paralleling methodological features of the ISIS and GUSTO consortia. Site recruitment involved tertiary centers such as Policlinico Gemelli and community hospitals affiliated with the Italian National Health Service; data monitoring and endpoint adjudication engaged committees similar to those in trials by the New England Journal of Medicine collaborators. Statistical planning incorporated intention-to-treat analyses and prespecified subgroup assessments inspired by designs seen in Framingham Heart Study follow-ups and multicenter trials like SOLVD.

Primary findings

The initial GISSI trial(s) demonstrated a mortality reduction associated with early thrombolytic strategies and particular pharmacologic regimens in the acute phase of Myocardial infarction, comparable to contemporaneous results from ISIS-2 and GUSTO. Key reported outcomes included lower short-term mortality and trends toward reduced reinfarction among patients receiving timely Thrombolytic therapy and adjunctive antiplatelet treatments akin to those studied in CAPRIE and CURE contexts. The trials also provided evidence supporting early use of agents targeting neurohormonal pathways, resonating with findings from CONSENSUS and SOLVD trials in heart failure populations.

Secondary analyses and subgroup results

Extensive secondary analyses explored heterogeneity of treatment effects across age groups, sex, infarct location, and concomitant therapies, with comparisons to subgroup frameworks used in MERIT-HF and RALES. Prespecified subgroup reports examined outcomes in elderly patients, women, and those with prior Stroke or diabetes mellitus, aligning with demographic inquiries common to trials like HOPE and CHARM. Additional analyses investigated timing of reperfusion, interactions with beta-blockers and ACE inhibitors similar to research in CAPRICORN, and bleeding risk profiles that paralleled safety assessments from Efficacy and Safety Trials in antithrombotic development.

Impact on clinical practice and guidelines

Results from the GISSI program influenced guideline committees including panels of the European Society of Cardiology and national recommendations within Italy and contributed to international guideline documents shaped by collaborators from the World Heart Federation and the American College of Cardiology. The pragmatic nature of GISSI facilitated adoption of early thrombolysis, broader use of antiplatelet agents, and attention to neurohormonal blockade in postinfarction care, echoing shifts documented in guideline updates from bodies such as the National Institute for Health and Care Excellence and the American Heart Association/American College of Cardiology. The trials helped inform health-policy dialogues within the European Union on acute cardiac care delivery.

Criticisms and limitations

Critiques of the GISSI program paralleled broader debates about open-label pragmatic trials versus blinded efficacy studies as raised in discourse around GUSTO and ISIS methodologies. Observers pointed to limited blinding, variability in site practices across hospitals in Italy, and evolving standards of care—such as primary percutaneous coronary intervention favored by centers like Ospedale San Raffaele—that complicated applicability to later eras dominated by interventional cardiology exemplified by the COURAGE and FRISC-II trials. Some statistical commentators compared endpoint adjudication and subgroup multiplicity concerns to debates in the PROVE-IT and EVEREST discussions. Despite these limitations, GISSI’s large sample sizes and real-world recruitment enhanced external validity akin to population-based cohorts such as Framingham Heart Study.

Category:Cardiology trials